Alten R, Lorenz H-M, Mariette X, et al. Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2-year results from the real-world ACTION study. EULAR 2017, FRI0245.
RA-patiënt met kanker kan veilig worden behandeld met checkpointremmer
mei 2023 | Dermato-oncologie, Immuuntherapie, Longoncologie, RA